Nishikawa Hiroshi, Ozaki Yasuhiko, Nakanishi Tamao, Blomgren Klas, Tada Toyohiro, Arakawa Atsushi, Suzumori Kaoru
Department of Obstetrics and Gynecology, Nagoya City University Medical School, Mizuho-cho, Mizuho, Nagoya 467-8601, Japan.
Gynecol Oncol. 2004 Mar;92(3):881-6. doi: 10.1016/j.ygyno.2003.11.017.
The aim of this study was to investigate the contribution of cathepsin B and cystatin C to the mechanisms of invasion by ovarian cancer.
Using surgical materials from patients with ovarian cancer, immunohistochemistry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting analysis were performed using antibodies against cathepsin B or cystatin C. Serum levels of cathepsin B and cystatin C in patients with benign and malignant ovarian lesions were determined by enzyme-linked immunosorbent assay (ELISA). An invasion assay using an ovarian cancer cell line was performed by addition of cystatin C or specific inhibitors of cathepsin B.
While immunohistochemical staining of cathepsin B and cystatin C was evident in cancer cells and associated stromal tissue, this was not the case in benign tumors. The malignancies were also found to be positive for cathepsin B and cystatin C by SDS-PAGE and Western blotting analysis. No significant difference in serum cathepsin B levels was observed between patients with benign and malignant disease. However, the concentration of cystatin C in cases with ovarian cancer was significantly higher in benign cases (P<0.0001) and in healthy controls (P<0.0001). Invasion by cancer cells was dose-dependently suppressed by cystatin C and cathepsin B inhibitors.
The results provided convincing evidence that cathepsin B and cystatin C may contribute to the mechanisms of invasion of ovarian cancer.
本研究旨在探讨组织蛋白酶B和胱抑素C在卵巢癌侵袭机制中的作用。
利用卵巢癌患者的手术材料,采用抗组织蛋白酶B或胱抑素C的抗体进行免疫组织化学、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质印迹分析。通过酶联免疫吸附测定(ELISA)测定良性和恶性卵巢病变患者血清中组织蛋白酶B和胱抑素C的水平。通过添加胱抑素C或组织蛋白酶B的特异性抑制剂,使用卵巢癌细胞系进行侵袭试验。
组织蛋白酶B和胱抑素C在癌细胞及相关基质组织中的免疫组织化学染色明显,但在良性肿瘤中并非如此。通过SDS-PAGE和蛋白质印迹分析还发现恶性肿瘤组织蛋白酶B和胱抑素C呈阳性。良性和恶性疾病患者血清组织蛋白酶B水平未观察到显著差异。然而,卵巢癌患者中胱抑素C的浓度在良性病例(P<0.0001)和健康对照(P<0.0001)中显著更高。胱抑素C和组织蛋白酶B抑制剂可剂量依赖性地抑制癌细胞的侵袭。
结果提供了令人信服的证据,表明组织蛋白酶B和胱抑素C可能参与卵巢癌的侵袭机制。